Inhibiting ERK5 overcomes breast cancer resistance to anti-HER2 therapy by targeting the G1/S cell cycle transition.
Zhang J, Pearson AJ, Sabherwal N, Telfer BA, Ali N, Kan K, Xu Q, Zhang W, Chen F, Li S, Wang J, Gray NS, Risa-Ebrí B, Finegan KG, Cross MJ, Giurisato E, Whitmarsh AJ, Tournier C.
Zhang J, et al. Among authors: sabherwal n.
Cancer Res Commun. 2022 Mar 10;2(3):131-145. doi: 10.1158/2767-9764.CRC-21-0089.
Cancer Res Commun. 2022.
PMID: 36466034
Free PMC article.